Guide Note:
Tremelimumab, formerly ticilimumab, is a drug produced by Pfizer. Clinical studies have been ongoing for a treatment for melanoma using trememlimumab. Tremelimumab works by boosting the immune system to target and attack tumor cells. Phase one clinical trails showed safety in administering up to 15 mg to patients with advanced melanoma.
In April 2008, Pfizer announced discontinuation of the phase three clinical trials for trememelimumab. Clinical trials showed that it did no better for patients with advanced melanoma than chemotherapy.
Fast Facts:
- Used to treat melanoma
- Fully human monoclonal antibody
- Antibodies to a protein called CTLA-4
- Studies have shown tumor regressions
- Ongoing studies on several types of cancer
Disclaimer: The content in this page is not a substitute for professional medical advice. Please contact your doctor before taking Tremelimumab.
- Also try: Melanoma
Tremelimumab News and Information
- Forbes: Pfizer's Setback Weighs On Medarex (April 2, 2008)
- Pfizer, which said it will continue to analyze the trial data, plans to work with patients receiving tremelimumab to determine how to proceed with treatment. The company plans to release the data at the American Society for Clinical Oncology's annual meeting in June.
- Reuters: UPDATE 1-Pfizer halts melanoma trial as drug fails (April 1, 2008)
- "We continue to focus on additional studies involving tremelimumab alone and in combination with other therapies which are currently ongoing in patients with several types of cancer," Baum said.
- Forbes: Targeting Melanoma (October 15, 2007)
- Wikipedia: Tremelimumab
- American Medical Association: Tremelimumab
- Drugs of the Future: Tremelimumab
Tremelimumab Research and Blogs
- ClinicalTrials.gov: Tremelimumab Clinical Trials
- PubMed: Novel therapies targeting the immune system.. (March 17, 2008)
- Cancer Investigation The Role of the CTLA4 Blockade in the Treatment.. (October 2007)
- The Oncologist: Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte–Associated.. (July 2007)
- Health Blog (WSJ): Pfizer Skin Cancer Drug Fails Clinical Test (April 2, 2008)
- This result, Tremelimumab, is currently a stub, a brief collection of the best links for this story. The page will be updated as we find more information.
- Help Mahalo complete this search! Let us know if you've found additional quality links about Tremelimumab on Google, Del.icio.us, Digg or elsewhere, and we can expand this result.